-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Verve Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2019 to Q1 2025.
- Verve Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $11.2M, a 8.06% increase year-over-year.
- Verve Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $44.1M, a 17.8% increase year-over-year.
- Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $43.3M, a 23.2% increase from 2023.
- Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $35.1M, a 56.2% increase from 2022.
- Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22.5M, a 218% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)